Aspire Biopharma Files 2024 10-K
Ticker: ASBPW · Form: 10-K · Filed: Apr 7, 2025 · CIK: 1847345
Sentiment: neutral
Topics: 10-K, pharmaceuticals, company-information
TL;DR
Aspire Biopharma filed its 2024 10-K. Check financials.
AI Summary
Aspire Biopharma Holdings, Inc. filed its 2024 10-K on April 7, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as PowerUp Acquisition Corp., is involved in the pharmaceutical preparations industry. Its principal executive offices are located at 194 Candelaro Drive, #233, Humacao, PR 00791.
Why It Matters
This filing provides investors with a comprehensive overview of Aspire Biopharma's financial performance and business operations for the fiscal year 2024, crucial for investment decisions.
Risk Assessment
Risk Level: low — The provided text is a header and basic company information from a 10-K filing, lacking specific financial performance details or forward-looking statements that would indicate higher risk.
Key Players & Entities
- Aspire Biopharma Holdings, Inc. (company) — Filer
- 2024-12-31 (date) — Fiscal Year End
- 2025-04-07 (date) — Filing Date
- PowerUp Acquisition Corp. (company) — Former Company Name
- 194 Candelaro Drive, #233, Humacao, PR 00791 (address) — Business Address
FAQ
What is Aspire Biopharma Holdings, Inc.'s primary industry?
Aspire Biopharma Holdings, Inc. is in the Pharmaceutical Preparations industry, with SIC code 2834.
When did Aspire Biopharma Holdings, Inc. file its 10-K report?
The company filed its 10-K report on April 7, 2025.
What was the previous name of Aspire Biopharma Holdings, Inc.?
The company was formerly known as PowerUp Acquisition Corp. and PowsedrUp Acquisition Corp.
Where are Aspire Biopharma Holdings, Inc.'s principal executive offices located?
The principal executive offices are located at 194 Candelaro Drive, #233, Humacao, PR 00791.
For which fiscal year is this 10-K report filed?
This 10-K report is for the fiscal year ending December 31, 2024.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on April 7, 2025 regarding Aspire Biopharma Holdings, Inc. (ASBPW).